GEP20104875B - Pyrimidine derivatives for the treatment of abnormal cell growth - Google Patents

Pyrimidine derivatives for the treatment of abnormal cell growth

Info

Publication number
GEP20104875B
GEP20104875B GEAP20059703A GEAP2005009703A GEP20104875B GE P20104875 B GEP20104875 B GE P20104875B GE AP20059703 A GEAP20059703 A GE AP20059703A GE AP2005009703 A GEAP2005009703 A GE AP2005009703A GE P20104875 B GEP20104875 B GE P20104875B
Authority
GE
Georgia
Prior art keywords
treatment
cell growth
abnormal cell
pyrimidine derivatives
prodrug
Prior art date
Application number
GEAP20059703A
Inventor
John Charles Kath
Michael Joseph Luzzio
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20104875(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GEP20104875B publication Critical patent/GEP20104875B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

A compound of the formula (1), or a pharmaceutically acceptable salt thereof, solvate, hydrate or prodrug, (values R1, R2, R3, R4, and n are as defined in the description), a pharmaceutical composition containing them and use thereof for treatment of abnormal cell growth.
GEAP20059703A 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth GEP20104875B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
GEP20104875B true GEP20104875B (en) 2010-01-11

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP20059703A GEP20104875B (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Country Status (27)

Country Link
EP (1) EP1751143A1 (en)
JP (1) JP4099212B2 (en)
KR (1) KR100886990B1 (en)
CN (2) CN1953974A (en)
AP (1) AP2241A (en)
AR (1) AR049097A1 (en)
AU (2) AU2005243397A1 (en)
BR (1) BRPI0511138A (en)
CA (1) CA2566707A1 (en)
CR (1) CR8749A (en)
EA (1) EA200601796A1 (en)
EC (1) ECSP066997A (en)
GE (1) GEP20104875B (en)
GT (1) GT200500113A (en)
IL (1) IL178828A0 (en)
MA (1) MA28583B1 (en)
MX (1) MXPA06011890A (en)
NL (2) NL1029045C2 (en)
NO (1) NO20064576L (en)
NZ (1) NZ550448A (en)
PA (1) PA8632601A1 (en)
PE (1) PE20060240A1 (en)
TN (1) TNSN06370A1 (en)
TW (1) TWI303635B (en)
UY (1) UY28894A1 (en)
WO (1) WO2005111023A1 (en)
ZA (1) ZA200608394B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
UA89123C2 (en) * 2005-12-21 2009-12-25 Пфайзер Продактс Инк. Pyrimidine derivatives for the treatment of abnormal cell growth
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
CA2693594A1 (en) * 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
HUE035029T2 (en) * 2008-05-21 2018-03-28 Ariad Pharma Inc Phosphorous derivatives as kinase inhibitors
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
JPWO2014174745A1 (en) * 2013-04-26 2017-02-23 国立大学法人京都大学 Eg5 inhibitor
CN109608444B (en) * 2018-11-27 2022-02-11 中国药科大学 Isoindolinone-containing ERK inhibitor and preparation method and application thereof
CN111732548B (en) * 2020-06-11 2022-06-17 浙江大学 N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
AP2385A (en) * 2002-12-20 2012-03-23 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
MXPA06011890A (en) 2006-12-14
KR20070012477A (en) 2007-01-25
PE20060240A1 (en) 2006-04-01
ZA200608394B (en) 2008-05-28
CA2566707A1 (en) 2005-11-24
TNSN06370A1 (en) 2008-02-22
ECSP066997A (en) 2007-02-28
GT200500113A (en) 2006-01-10
EP1751143A1 (en) 2007-02-14
AR049097A1 (en) 2006-06-28
KR100886990B1 (en) 2009-03-04
NZ550448A (en) 2010-11-26
BRPI0511138A (en) 2007-11-27
AU2009238255A1 (en) 2009-12-03
NL1029045A1 (en) 2005-11-15
CN1953974A (en) 2007-04-25
TWI303635B (en) 2008-12-01
JP2007537234A (en) 2007-12-20
TW200539871A (en) 2005-12-16
AP2241A (en) 2011-06-01
IL178828A0 (en) 2007-03-08
AP2006003790A0 (en) 2006-10-31
UY28894A1 (en) 2005-12-30
NL1031845A1 (en) 2006-07-31
NL1031845C2 (en) 2006-11-23
PA8632601A1 (en) 2006-06-02
NL1029045C2 (en) 2006-06-02
CN102127058A (en) 2011-07-20
EA200601796A1 (en) 2007-04-27
CR8749A (en) 2006-12-05
AU2005243397A1 (en) 2005-11-24
NO20064576L (en) 2006-11-07
MA28583B1 (en) 2007-05-02
WO2005111023A1 (en) 2005-11-24
JP4099212B2 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
GEP20104895B (en) Preparation of pregabalin and related compounds
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
MXPA06013164A (en) Pyrimidines derivatives for the treatment of abnormal cell growth.
TW200732303A (en) Novel fused pyrrole derivatives
TW200740758A (en) Benzoquinazoline derivatives
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
SE0202463D0 (en) Novel compounds
MX2007010532A (en) 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus.
GEP20104964B (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
MX2007003546A (en) Indozolone derivatives as 11b-hsd1 inhibitors.
MXPA05012415A (en) Isoquinoline derivatives and their use as gfat inhibitors.
MX2007013624A (en) Protein kinase inhibitors.
MY137156A (en) Dual nk1/nk3 derivatives
MX2007004302A (en) Pi3 kinase gamma inhibitors for the treatment of anaemia.
TW200639156A (en) New compounds
TW200626145A (en) Heterocyclic compounds and thrombopoietin receptor activators
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
HK1114516A1 (en) Substituted sulfoxide compounds, methods for preparing the same and use thereof